AstraZeneca plans to expand its biologics manufacturing center in Frederick, MD, investing more than $200 million to increase production capacity to support its maturing pipeline. Biologics currently represent nearly 50% of the company’s overall pipeline.   The Frederick biologics manufacturing center is an FDA licensed, large-scale cell culture production facility, with hundreds of thousands of square feet of administrative, production, warehouse, lab and utility space. The expansion, expected ...